Congratulations to our amazing UPMC Hematology & Oncology Fellowship Program class of 2022! So incredibly proud of all of you Lilit Karapetyan Max JL Saba Shaikh UPMC Hillman Cancer Center

Group photo of the home crew from Fox Chase 📸Fox Chase Cancer Center Temple Health at #vailworkshop #MCCR22 ASCO AACR with Ben Miron Julia Judd, DO Saba Shaikh and Cyrus Mazidi - snapped at a rare moment when we were not hard at work on protocols! Photo credit Ronan Hsieh, MD, MS pic.x.com/jzlDargSWr

An important study by Dr. E Mittendorf Of those with clinical node- TNBC ~10% of T1ab tumors, + ~15% of T1c tumors will be node + at surgery. Important implications for who needs preop tx + pembro. Consider axillary US in these pts OncoAlert pubmed.ncbi.nlm.nih.gov/35941343/

We can finally complete the table with all results (PFS and OS) from the CDK4/6 inhibitors phase III trials in HR+/HER2- MBC 👇🏽 OS in Paloma-2 was the only outcome did not meet significant difference 🪄🤨

In the middle of a discombobulated week, a multiple bad scans-kind of a day, a running 2 hours behind day, there’s a person that just wants to tell you how grateful they are to be alive, for the team’s care of them over the years. Suddenly time stops. And that’s oncology folks 🙏

A wonderful collaborative effort with 4 institutions Lubna Chaudhary MD, MS Yara Abdou, MD, MSCR Saba Shaikh Arya Roy Real world outcome data with sacituzumab govitecan in metastatic breast cancer.

Significant OS benefit of pembro. Now questions are: do we need that much chemo; do we need adj pembro after pCR; is there signature of response; what do we do with T1c? Great discussion below. SABCS Sara Tolaney Kate Lathrop #sabcssnippets

Speaking of ways to make sure EVERYONE has access to learning at #SABCS24, things I noticed: 1️⃣ sign language interpreter 2️⃣ child care on site (I peeked in, they were multiple kids having fun) 3️⃣ multiple mothers rooms for pumping 4️⃣ prayer rooms #SABCS24 SABCS

Otto Metzger (Otto Metzger) presents the practice-changing results from the #PATINA phase 3 trial: adding palbociclib to maintenance ET after 1L THP for HR+/HER2+ MBC significantly and meaningfully improved PFS (44 vs 29 months, HR 0.74, p=0.007). 44 months!!!!!!!!!!!!!!!!!!!!!!!!

How are results from DB11 going to change early breast cancer treatment?

Thank you Dr Modi for joining us for a great discussion! Excited to see the data soon!

Grateful for this opportunity and committed to improve diversity in clinical trials ECOG-ACRIN Cancer Research Group

Robust benefit of SG+pembro in first line tnbc. Still don’t know what to do post kn522 since very few such patients included but this should be a new soc. Sara Tolaney #ASCO2025